ABSTRACT
The growing progress in automation technology, data management, combinatorial chemistry, and knowledge on cancer biology drives high-throughput screening (HTS) technology, characterized by selectivity, rapidity, and reliability. It is highly recommended in modern drug innovation processes as it detects more biologically relevant characteristics of active compounds in living systems. HTS assays can be broadly classified into two categories: cell-based assays and target-based biochemical assays. Cell-based HTS tests are performed mainly in multiwell plates to escalate the number of wells per plate for HT rates and are handled using an automatic robotic system. HTS platform widely uses static cultures, wherein the intermittent medium change brings in contamination risk and undesirable culture conditions. Cytotoxicity measurements based on quantification of viable cell number using conventional hemocytometer are time-consuming and labor intensive. As HTS involves the use of a small amount of culture medium, detection of cytotoxicity is achieved by two noninvasive, online monitored methods: electrochemical and optical.
